SCHEMBL23577408

SCHEMBL23577408

C/C=C\c1ccc2c(N(C)c3ccccc3)nc3nncn3c2c1

nearest known ligand 0.36

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 2/20 0.34
▸ MAPT P10636 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ CSNK2A1 P68400 2/20 0.32
▸ CSNK2A2 P19784 1/20 0.32
▸ CSNK2B P67870 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ EGFR P00533 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23601402 1.00 PDE5A (0.34) PDE5AMAPTSMN1; SMN2CSNK2A1CSNK2A2
SCHEMBL23577410 1.00 PDE5A (0.34) PDE5AMAPTSMN1; SMN2CSNK2A1CSNK2A2
SCHEMBL29909153 1.00 PDE5A (0.34) PDE5AMAPTSMN1; SMN2CSNK2A1CSNK2A2
SCHEMBL23601012 0.89 ALOX15 (0.33) PDE5AMAPTSMN1; SMN2CSNK2A1CSNK2A2
SCHEMBL29909507 0.88 CSNK2A1 (0.37) PDE5AMAPTSMN1; SMN2CSNK2A1CSNK2A2
SCHEMBL30961002 0.88 MAPT (0.35) PDE5AMAPTSMN1; SMN2CSNK2A1CSNK2A2
SCHEMBL23576806 0.88 MAPT (0.35) PDE5AMAPTSMN1; SMN2CSNK2A1CSNK2A2
SCHEMBL23576972 0.88 CSNK2A1 (0.37) PDE5AMAPTSMN1; SMN2CSNK2A1CSNK2A2
SCHEMBL23577003 0.86 CSNK2A1 (0.33) PDE5AMAPTSMN1; SMN2CSNK2A1CSNK2A2
SCHEMBL29909346 0.86 CSNK2A1 (0.33) PDE5AMAPTSMN1; SMN2CSNK2A1CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 — — US disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 — — US disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 — — EP disclosed
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 — — EP disclosed
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-06 — — US disclosed
US-11845723-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2023-12-19 — — US disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 — — US disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 — — US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 — — WO disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK PDE5A 1924/4885MAPT 4206/4885SMN1; SMN2 4737/4885
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK PDE5A 1924/4885MAPT 4206/4885SMN1; SMN2 4737/4885
US-11845723-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK PDE5A 1924/4885MAPT 4206/4885SMN1; SMN2 4737/4885
US-20240182476-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK PDE5A 1924/4885MAPT 4206/4885SMN1; SMN2 4737/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK PDE5A 1924/4885MAPT 4206/4885SMN1; SMN2 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback